Key Drivers
- Strong liquidity
- High cash burn
- Ongoing dilution
AIAI Summary
TYRA is now a clinical-proof investment: its well-funded balance sheet offsets near-term financing risk, but upside depends on whether dabogratinib's promising yet tiny SURF302 dataset translates into durable, reproducible responses sufficient for registrational development. Investors should await longer-term efficacy and safety data, as dilution has raised the clinical bar required to justify meaningful per-share upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High cash burn
- •Ongoing dilution
TYRA's strong liquidity and low leverage provide funding flexibility, but high cash burn, persistent losses, dilution risk, and a premium-to-book valuation make it a speculative investment.
Price Behavior
Key Price Behavior Insights:
- •Volatile rebound
- •Key resistance
- •Fragile support
TYRA's volatile last-month rebound above its $25.24 average is constructive, but a sustained move above $26.70–$28.65 is needed to confirm upside while $24.35–$25.00 support must hold.
Sharp rebound from $22.03 to $25.73 in one week
Sentiment & News
Key News Insights:
- •Mixed trial data
- •Major equity raise
- •Legal investigation
Tyra's mixed Phase 2 dabogratinib results triggered a sharp selloff, followed by a $400M capital raise and investor-law-firm scrutiny.
Near-term sentiment remains negative as clinical uncertainty and dilution concerns pressure the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings